Send me real-time posts from this site at my email

March 18 - Trading List: Updates, Analyst Actions, Our Take - CRWD, HZNP

Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.

Crowdstrike price target raised to $250 from $220 at RBC Capital

RBC Capital analyst Matthew Hedberg raised the firm's price target on Crowdstrike to $250 from $220 and keeps an Outperform rating on the shares. The company's Q4 performance was "strong" as annual recurring revenue crossed the $1B threshold and its free cash flows of $97M topped expectations, the analyst tells investors in a research note. Hedberg adds that Crowdstrike remains one of his "favorite growth ideas".

Crowdstrike FY22 revenue growth guidance 'impressive,' says Jefferies

Jefferies analyst Brent Thill noted that Crowdstrike reported "a big beat and raise" in Q4, but "most impressively" guided to FY22 year-over-year revenue growth of 50-51%, which he notes is about 1,000 basis points above the Street's 41% growth estimate. The Q4 results "were a great indicator of how impressive this story is, and we don't see the cyber tailwinds slowing down soon with the competitive moat widening," said Thill, who keeps a Buy rating and $275 price target on Crowdstrike shares.

Our Take:  "CRWD just reported earnings and are doing very well. Many analysts raised price targets today. These guys are executing well and are in the right business for present times. Cyber security is a must have for many. The only trouble we have here is the valuations do get over-extended at times. Fairly volatile so buying dips and selling peaks may work for you."

$CRWD, CrowdStrike Holdings, Inc. / H1

Horizon Therapeutics price target raised to $125 from $110 at Stifel

Stifel analyst Annabel Samimy raised the firm's price target on Horizon Therapeutics to $125 from $110 and keeps a Buy rating on the shares after the closing of the company's Viela Bio acquisition. The analyst, who maintains Horizon as a Select Pick, sees Horizon leveraging the power of its orphan platform and immunology expertise to drive Uplizna expansion opportunities and other earlier immunology candidates from Viela.

Our Take:  "Still one of the best growth stories in the biotech space. Analysts continue to raise price targets and give Buy ratings."

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)!

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue